InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. More Details
Flawless balance sheet with limited growth.
Share Price & News
How has InspireMD's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NSPR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: NSPR's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: NSPR underperformed the US Medical Equipment industry which returned 36.7% over the past year.
Return vs Market: NSPR underperformed the US Market which returned 44.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is InspireMD's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 months ago | Simply Wall StTrade Alert: Gary Roubin At InspireMD, Inc. (NYSEMKT:NSPR), Has Just Spent US$150k Buying 52% More Shares
7 months ago | Simply Wall StAnalysts Have Been Trimming Their InspireMD, Inc. (NYSEMKT:NSPR) Price Target After Its Latest Report
Is InspireMD undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NSPR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NSPR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NSPR is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: NSPR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NSPR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NSPR is good value based on its PB Ratio (1.1x) compared to the US Medical Equipment industry average (4.7x).
How is InspireMD forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if NSPR's forecast earnings growth is above the savings rate (2%).
Earnings vs Market: Insufficient data to determine if NSPR's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: NSPR's revenue (43.8% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: NSPR's revenue (43.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NSPR's Return on Equity is forecast to be high in 3 years time
How has InspireMD performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NSPR is currently unprofitable.
Growing Profit Margin: NSPR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NSPR is unprofitable, but has reduced losses over the past 5 years at a rate of 1.4% per year.
Accelerating Growth: Unable to compare NSPR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NSPR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.1%).
Return on Equity
High ROE: NSPR has a negative Return on Equity (-26.87%), as it is currently unprofitable.
How is InspireMD's financial position?
Financial Position Analysis
Short Term Liabilities: NSPR's short term assets ($46.3M) exceed its short term liabilities ($2.9M).
Long Term Liabilities: NSPR's short term assets ($46.3M) exceed its long term liabilities ($1.8M).
Debt to Equity History and Analysis
Debt Level: NSPR is debt free.
Reducing Debt: NSPR currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NSPR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: NSPR has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 8.5% each year
What is InspireMD current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NSPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NSPR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NSPR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NSPR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NSPR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Marvin Slosman (55 yo)
Mr. Marvin L. Slosman has been President, Chief Executive Officer and Director of InspireMD, Inc. since January 1, 2020. Mr. Slosman served as Chief Operating Officer for MEDCURA Incorporated from May 2019...
CEO Compensation Analysis
Compensation vs Market: Marvin's total compensation ($USD1.38M) is above average for companies of similar size in the US market ($USD526.91K).
Compensation vs Earnings: Insufficient data to compare Marvin's compensation with company performance.
Experienced Management: NSPR's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Experienced Board: NSPR's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 890.4%.
InspireMD, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: InspireMD, Inc.
- Ticker: NSPR
- Exchange: NasdaqCM
- Founded: 2005
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$47.044m
- Shares outstanding: 7.91m
- Website: https://www.inspiremd.com
Number of Employees
- InspireMD, Inc.
- 4 Menorat Hamaor Street
- Tel Aviv
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/12 05:31|
|End of Day Share Price||2021/06/11 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.